JNJ
Johnson & Johnson
Health Care / Pharmaceuticals / MedTech / New Brunswick, NJ
AnalystScope signal
Sell
Scheduled quote
$249
Base fair value
$167
Bear / base / bull
$142 / $167 / $182
Upside / downside
-33.0 downside
Confidence
Medium
Research updated Apr 8, 2026
Daily scheduled refresh as of Jul 21, 2026, 6:05 AM UTC. Fresh through Jul 22, 2026, 6:05 AM UTC.
Informational research only. Not personalized investment advice.
Model vs published view
Current model signal differs from the latest published analyst rating.
Live current-price moves may be widening the gap versus the latest published view.
Investment summary
Current view and thesis
Johnson & Johnson brings diversified healthcare resilience and solid cash generation, but the current valuation spread still looks more like a steady Hold than a strong rerating case.
Fair value $167 vs. current $249 (-33.0 downside). Current base fair value is $167 versus $249, implying -33.0 downside.
Key drivers
Diversified healthcare exposure keeps the earnings base steadier than single-product or narrower peers.
Solid free-cash-flow generation supports both capital return and downside protection.
A balanced pharma and medtech mix helps keep margin durability credible.
Key risks
Pipeline or product-cycle disappointment could soften the current long-run revenue base.
Litigation or liability treatment can still alter the market's confidence in distributable cash.
The current setup is steady, but not insulated from slower healthcare spending or portfolio friction.
What would change the view
Clearer pipeline support or stronger medtech acceleration would improve the setup.
A weaker litigation outlook or softer portfolio execution would reduce confidence in the base case.
A wider discount to the current fair-value range would make the defensive case more attractive.
Valuation
Price, range, and method support
Base case $167 / -33.0 downside / medium confidence
Price vs fair value
-32.9%
Model-implied return
Scheduled quote
$249
Fair value
$167
Valuation method stack
Weighted fair value $167
Published method weights
DCF (Base)
$172 | 50%
NTM P/E Multiple
$164 | 30%
EV/EBITDA Cross-check
$158 | 20%
| Case / method | Value | Weight / support |
|---|---|---|
| DCF (Base) | $172 | 50% |
| NTM P/E Multiple | $164 | 30% |
| EV/EBITDA Cross-check | $158 | 20% |
| Bear case | $142 | Mixed |
| Base case | $167 | Supportive |
| Bull case | $182 | Mixed |
Fundamental analysis
Reported evidence and normalized model base
Normalized annual basis: FY2025
Normalized figures are AnalystScope's annual valuation model base.
| Normalized metric | Latest value | Growth / margin context |
|---|---|---|
| Revenue | $91.4B | +3.7% YoY |
| Operating income | $25.1B | 27.5% margin |
| Net income | $19.6B | EPS proxy $8.15 |
| Free cash flow | $19.9B | 21.8% margin |
| EBITDA | $28.8B | 31.5% margin |
| Net cash / (debt) | -$2.0B | -2.2% of revenue |
| Metric | Reported | AnalystScope normalized | Basis note |
|---|---|---|---|
| Revenue (TTM) | $94.2B | $91.4B | Model revenue smooths portfolio churn and avoids over-reading one product cycle or divestiture period. |
| Operating Margin | Unavailable | 27.5% | Margin input keeps the durable pharma-plus-medtech base separate from temporary mix or launch-cost noise. |
| FCF (TTM) | $19.7B | $19.9B | FCF input adjusts for working-capital timing and keeps litigation and restructuring assumptions conservative. |
| Net Cash / (Debt) | ($17.8B) | ($2.0B) | Balance-sheet treatment does not assume all cash is fully distributable and keeps liabilities conservative. |
Fundamental snapshot
FY2025
Normalized annual model base
Revenue
+3.7% YoY
$91.4B
Op. margin
+0.7% pts
27.5%
FCF margin
+0.4% pts
21.8%
Revenue + margin trend
Annual normalized model-base history.
Revenue
Operating margin
AnalystScope annual model-base statements in USD across FY2023 | FY2024 | FY2025.
Income statement
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $85.2B | $88.1B | $91.4B |
| Gross Profit | $57.1B | $59.4B | $62.0B |
| Operating Income | $22.2B | $23.6B | $25.1B |
| EBITDA | $25.6B | $27.1B | $28.8B |
| Net Income | $17.0B | $18.3B | $19.6B |
Balance sheet
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & Investments | $40.0B | $41.0B | $42.0B |
| Total Debt | $46.0B | $45.0B | $44.0B |
| Net Cash / (Debt) | ($6.0B) | ($4.0B) | ($2.0B) |
| Total Assets | $177.0B | $181.0B | $186.0B |
| Total Liabilities | $103.0B | $104.0B | $105.0B |
| Shareholders' Equity | $74.0B | $77.0B | $81.0B |
Cash flow
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $20.9B | $21.9B | $23.1B |
| Depreciation & Amortization | $3.4B | $3.5B | $3.7B |
| Capital Expenditures | ($3.1B) | ($3.1B) | ($3.2B) |
| Free Cash Flow | $17.8B | $18.8B | $19.9B |
Model assumptions
Base-case inputs and sensitivity
Published AnalystScope assumptions; private edits do not change this base case.
Revenue CAGR (5Y)
4.5%
+/- 1.0% => +/-$5/sh
Why this level: This is AnalystScope's base-case growth assumption, not a guarantee. It sits below the latest FY model-base revenue pace (2025.0%), so the model does not extend current strength too far into the outer years. Current company context: Diversified healthcare exposure keeps the earnings base steadier than single-product or narrower peers.
Terminal Growth
2.5%
+/- 0.5% => +/-$4/sh
Why this level: This is AnalystScope's mature long-run growth assumption, not a perpetual hypergrowth claim. At 2.5%, it sits well below the 4.5% five-year revenue CAGR, so the model steps down from the explicit forecast period to a steadier long-run pace. For Johnson & Johnson, that means a durable franchise can keep compounding after year five without assuming today's faster growth profile lasts indefinitely.
WACC
8.0%
+/- 0.5% => -$6/sh
Why this level: This is AnalystScope's base-case cost-of-capital judgment, not a precise CAPM output. It reflects the current rates backdrop, equity risk premium, and the company's balance-sheet posture. Balance sheet remains flexible despite modest net debt
Operating Margin (Year 5)
28.5%
+/- 100 bps => +/-$4/sh
Why this level: This is AnalystScope's base-case margin view, not a promise of straight-line expansion. It keeps year-five margins close to today's model-base operating margin (27.5%), which implies the current margin structure is broadly durable. Margin input keeps the durable pharma-plus-medtech base separate from temporary mix or launch-cost noise.
Sensitivity drivers
Revenue CAGR (5Y)
4.5%
+/- 1.0% => +/-$5/sh
Terminal Growth
2.5%
+/- 0.5% => +/-$4/sh
WACC
8.0%
+/- 0.5% => -$6/sh
Operating Margin (Year 5)
28.5%
+/- 100 bps => +/-$4/sh
Confidence
Medium
Method outputs show moderate dispersion of +8.4%.
Why the model view could be wrong
Pipeline or product-cycle disappointment could soften the current long-run revenue base.
Litigation or liability treatment can still alter the market's confidence in distributable cash.
The current setup is steady, but not insulated from slower healthcare spending or portfolio friction.
Private analysis
Test your own assumptions in Scenario Builder
Private scenarios remain separate from AnalystScope's published base case.
Private workspace
Scenario Builder
Private scenario sandbox
This is a private modelling layer, not the public AnalystScope base case or printable snapshot. It keeps the public base case as the anchor, applies bounded changes to the four core valuation inputs, and updates your scenario fair-value estimate immediately.
Saved scenarios currently stay local to this browser for JNJ. Base-case rationale remains in the public assumptions section above. Your scenario output reprices the published valuation methods from projected operating anchors when those anchors are available, while keeping market-multiple and capital-structure assumptions anchored to the AnalystScope framework.
Editable assumptions
Adjust your scenario inputs within the displayed plausible range for this company. The workbench stays anchored to the public AnalystScope base case.
This is a bounded scenario tool, not a free-form spreadsheet. Values outside the displayed range snap back to the nearest allowed value when you leave the field.
Matches the published AnalystScope base case.
Revenue CAGR (5Y)
Public AnalystScope base case: 4.5% | +/- 1.0% => +/-$5/sh
Allowed range: 0.0% to 10.5%
Terminal Growth
Public AnalystScope base case: 2.5% | +/- 0.5% => +/-$4/sh
Allowed range: 1.0% to 4.0%
WACC
Public AnalystScope base case: 8.0% | +/- 0.5% => -$6/sh
Allowed range: 6.0% to 10.0%
Operating Margin (Year 5)
Public AnalystScope base case: 28.5% | +/- 100 bps => +/-$4/sh
Allowed range: 20.5% to 36.5%
Saved private scenarios
Save up to 5 named scenarios for JNJ. These are your scenarios: they never overwrite the public AnalystScope base case and remain clearly separate from public research.
Checking private workspace session...
Private scenario note
Keep a short thesis, main risk, or why this case differs from the published base case.
0 / 280
Notes stay local to this browser unless you sign in to the private workspace, and they never appear as published AnalystScope research.
No private scenarios saved yet. Make a change to the published base case, then save a named scenario here.
Published base case
Fair value
$167
Upside / Downside
-33.0 downside
Model signal
Sell
Published base-case output
Scenario output reprices the published DCF and multiple methods from projected year-5 revenue, margin, free cash flow, EBITDA, and EPS anchors. Market multiples and capital structure stay anchored to the published base framework.
Fair value
$167
$0/sh vs published base case
Upside / Downside
-33.0 downside
+0.0 pts vs published base case
Model signal
Sell
Unchanged versus the published base case.
Method movement inside the scenario
This breakdown shows what moved inside the published valuation framework when you edit the scenario. The published AnalystScope base case stays anchored, and any method without a clean projected anchor remains pinned to that framework.
Method rows below reflect the current edited scenario state, not just the saved scenario snapshots.
Influence tags are directional rather than exact attribution. They estimate which edited input is moving each method most by reverting one assumption at a time while the other edited inputs stay in place.
| Method | Published base | Edited scenario | Delta | How it moved / main drivers |
|---|---|---|---|---|
DCF (Base) DCF-style | 50% weight | $172 | $172 | $0/sh | Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case. |
NTM P/E Multiple P/E-style | 30% weight | $164 | $164 | $0/sh | Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case. |
EV/EBITDA Cross-check EV-based multiple | 20% weight | $158 | $158 | $0/sh | Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case. |
Weighted fair value Published framework result | Published framework result | $167 | $167 | -$0/sh | Moved Combines the repriced method outputs using the published AnalystScope weights. No single edited assumption is dominating this move in a material way. |
Published base case vs private scenarios
Compare the published AnalystScope base case against your saved private scenarios in one view. Saved scenarios remain local to this browser, and the table below reflects saved snapshots rather than any unsaved edits currently sitting in the editor.
Fair-value comparisons use the same workbench recalculation path as the editor above.
Published base case stays pinned as the anchor row.
| Scenario | Revenue CAGR (5Y) | Terminal Growth | WACC | Op. Margin (Y5) | Fair Value | Upside / Downside | Model Signal | Delta vs Base | Action |
|---|---|---|---|---|---|---|---|---|---|
AnalystScope base case PublishedOfficial AnalystScope anchor row. | 4.5% | 2.5% | 8.0% | 28.5% | $167 | -33.0 downside | Sell | Published anchor |
Supporting research
Quality, normalization, and monitoring evidence
Annual model base: FY2023 | FY2024 | FY2025
Thesis scorecard
Growth
ModerateGrowth is steadier than spectacular, with diversification doing more than a single blockbuster narrative.
Profitability
StrongMargins and cash conversion remain sturdy across a broad healthcare base.
Balance sheet
StrongThe balance sheet remains flexible even after conservative liability treatment.
Valuation
ModerateThe current multiple is not stretched, but neither is the fair-value spread unusually wide.
Execution / Resilience
StrongDiversification across pharma and medtech supports resilience.
Current source status
Quote: Daily scheduled refresh as of Jul 21, 2026, 6:05 AM UTC. Fresh through Jul 22, 2026, 6:05 AM UTC.
Reported fundamentals: Fundamentals refreshed 21 Jul 2026, 00:39 UTC. Fresh through 21 Jul 2026, 12:39 UTC.
Latest filing: 144 filed Jul 20, 2026. Filing refreshed Jul 21, 2026, 1:32 AM UTC. Fresh through Jul 21, 2026, 1:32 PM UTC.
Annual model-base income-statement, cash-flow, and balance-sheet metrics, plus cross-statement quality relationships with compact prior-FY direction cues, derived from the curated statement backbone.
Basis: FY2023 | FY2024 | FY2025. Live reported fundamentals remain available in the reconciliation section.
Operating and cash-flow trends
Revenue growth (1Y)
+3.7%
Gross margin
67.8%
Operating margin
27.5%
Operating margin change vs prior FY
+0.7 pts
EBITDA margin
31.5%
EBITDA margin change vs prior FY
+0.7 pts
Operating income growth (1Y)
+6.4%
Net margin
21.4%
FCF margin
21.8%
FCF margin change vs prior FY
+0.4 pts
FCF growth (1Y)
+5.9%
Balance sheet quality
Cash & investments
$42.0B
Total debt
$44.0B
Net cash / (debt)
Net debt $2.0B
Net cash / (debt) as % of revenue
Net debt 2.2% of revenue
Liabilities / assets
vs FY2024 (-1.0 pts)
56.5%
Cross-statement quality
Gross-to-operating spread
40.4 pts
Operating cash flow / net income
vs FY2024 (-0.0x)
1.2x
Operating cash flow / EBITDA
vs FY2024 (-0.0x)
0.8x
Free cash flow / net income
vs FY2024 (-0.0x)
1.0x
CapEx as % of revenue
vs FY2024 (-0.0 pts)
3.5%
CapEx as % of operating cash flow
vs FY2024 (-0.3 pts)
13.9%
CapEx / D&A
vs FY2024 (-0.0x)
0.9x
Cash & investments / total debt
vs FY2024 (+0.0x)
1.0x
Shareholders' equity as % of revenue
88.6%
Asset turnover
vs FY2024 (+0.0x)
0.5x
Compact model-base diagnostics for analyst triage, highlighting where the durable valuation base is diverging most clearly from the latest reported picture.
Adjustment focus
Large analyst adjustmentBalance sheet | Net Cash / (Debt) | +$15.8B / +17% of revenue
Revenue momentum
Stable+3.7% latest 1Y growth
vs +3.4% prior 1Y
Operating margin trend
Stable27.5% latest margin
+67 bps vs prior FY
FCF margin trend
Stable21.8% latest FCF margin
+43 bps vs prior FY
Balance-sheet posture
StableNet debt 2.2% of revenue
vs Net debt 4.5% of revenue prior FY
How to read this
Reported = the latest company-reported figure. Model base = AnalystScope's comparable operating base used for valuation and thesis work. It may include standardization, conservative balance-sheet treatment, working-capital cleanup, and through-cycle adjustments when current reported numbers do not look durable.
This is an analyst model base, not a claim of perfect adjusted truth. Larger gaps can reflect deliberate cyclical or base-case adjustments, not just light accounting cleanup.
Why the model base differs
For JNJ, the model base is meant to reflect durable diversified healthcare economics rather than temporary product-cycle or portfolio-shift noise.
Rows are sorted by largest comparable adjustment first.
| Metric | Model base | Live reported | Variance vs reported | Adjustment size | Why lower / higher? |
|---|---|---|---|---|---|
Net Cash / (Debt) | ($2.0B) FY2025 model base | ($17.8B) Live reported balance sheet | +$15.8B / +17% of revenue | Large analyst adjustment | Model base is less conservative than the live reported balance-sheet figure because the latest reported balance does not appear fully representative. It does not assume all cash is fully distributable and keeps liabilities conservative. |
Revenue (TTM) | $91.4B FY2025 model base | $94.2B Live reported TTM | -$2.8B / -3% | Close to reported | Model base is lower than live reported because the thesis does not carry the current revenue run-rate straight into the durable operating base. It smooths portfolio churn and avoids over-reading one product cycle or divestiture period. |
FCF (TTM) | $19.9B FY2025 model base | $19.7B Live reported TTM | +$200.0M / +1% | Close to reported | Model base is higher than live reported because the model does not assume the latest cash-flow drag is fully durable. It adjusts for working-capital timing and keeps litigation and restructuring assumptions conservative. |
Operating Margin | 27.5% FY2025 model base | Unavailable Live reported margin | Unavailable | Unavailable | AnalystScope keeps a separate model base when the latest reported figure is unavailable or not directly comparable. It keeps the durable pharma-plus-medtech base separate from temporary mix or launch-cost noise. |
Near-term catalysts
Pipeline and portfolio commentary remain the nearest catalysts for estimate changes.
Cash-conversion quality and liability framing matter for the downside case.
Margin durability across the mixed portfolio still shapes confidence in the base case.
What we are watching
Whether the pharma and medtech mix keeps supporting a durable margin profile.
How conservatively the market is treating litigation and liability risk versus the model base.
Any sign that diversified healthcare resilience is being under- or over-valued in the current price.
| Date | Event | Published rating | Note |
|---|---|---|---|
| Apr 8, 2026 | New | Hold | Started coverage with a Hold view on healthcare resilience and a moderate fair-value spread. |